Press Releases

Year

Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

January 13, 2020

-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan Drug Designation from the FDA for the treatment of multiple myeloma- -First...

Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020

DURHAM, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that Matt Kane, co-founder and CEO, will present at the 38 th...

INVESTORS & MEDIA

Overview
Corporate Governance
Press Releases
Events & Presentations
Stock Information
SEC Filings
Investor FAQs
Corporate Deck

Investor Tools

Print Page
Email Page
Email Alerts
Document Request
Contact IR
RSS Feeds

Contact Info

919.314.5512

Partner
Career Opportunities

About Us

At Precision, leaders in genome editing utilize the ARCUS® editing platform to eliminate cancers, cure genetic diseases, and create safer, more productive food sources.

Quick Links

> Home
> Our Team
> Our Approach
> Careers
> Contact

Legal

> Terms of Use
> Privacy Policy